Drug Cost Spiral Breaks Employer Benefit Plans
Rising drug costs and opaque PBM practices are forcing employers to treat prescription benefits as enterprise risk. In 2026, U.S….
The GLP-1 Effect: How Weight-Loss Drugs Are Changing the Business of Healthcare
This Cheddar segment explores the growing impact of GLP-1 medications on healthcare, highlighting how these drugs are reshaping conversations around…
SHARx CEO Warns Companies May Be Overlooking Their Biggest Cost Driver in Healthcare
As healthcare and pharmacy costs surge, employers are under pressure to protect their workforce without sacrificing financial stability. SHARx CEO…
Holding patients hostage: Why drug prices in the US are higher than ever
Rising drug costs are an increasingly important priority in the US. Americans spend more on healthcare than any other country…
SHARx Calls for Accountability as Policymakers Target PBM Practices Nationwide
Rising drug costs and persistent access barriers are prompting employers to scrutinize the role of PBMs in determining how care…
SHARx: Drug Pricing Isn’t Just Broken, It’s Protected
Growing regulatory scrutiny and industry reporting suggests that high drug prices persist not just because of cost, but because of…
SHARx Analyzes TrumpRx: Transparency on Drug Costs Doesn’t Resolve Pricing and Access Gatekeeping
The launch of the TrumpRx platform has put prescription drug pricing back in the spotlight, but lower list prices are…
Business Insight Journal Interview with Paul Pruitt, Co-founder and Chief Growth Officer at SHARx
Paul Pruitt, co-founder of SHARx, argues that the U.S. drug affordability crisis is driven by a lack of transparency and…
Reclaiming Affordability: A Sustainable Way to Deliver Prescription Benefits
This article, Paul Pruitt (CGO of SHARx) explores how opaque pharmacy pricing models continue to drive high prescription drug costs…
Providing Access to Uncovered Specialty Medications with Paul Pruitt (SHARx)
In this episode of the Empowered Patient Podcast, Paul Pruitt, CGO of SHARx, shares how rising specialty drug costs are putting…